Member Info for mulledwine

African Aura Mining Inc. ("African Aura" or the "Company"), the TSX‑V (AUR) and AIM (AAAM) listed exploration and development company is pleased to announce an initial independent National Instrument 43-101 compliant Mineral Resource Estimate at its 100% owned Nkout iron ore project in southern Cameroon. · Maiden Inferred mineral resource estimate of 1.04 billion tonnes of iron ore at 34% Fe · Management targeting 4 billion tonnes at Nkout and surrounding anomalies · Estimate covers a 3km section of a 20km long magnetic anomaly · Metallurgical test work on the magnetite BIF proves high grade concentrate · Metallurgical test work on the oxidized BIF shows sinter fines potential · Potential for direct shipping ore ("DSO") being investigated · 2011 drilling campaign underway and expected to total 25,000m

http://www.investegate.co.uk/Article.aspx?id=201102010700094210A

Clive Watson, Chief Executive of Capital Pub Company, said: "Current trading remains strong and we remain confident of the resilience of the London market which continues to be buoyant. In addition, we continue to grow our quality portfolio of iconic London pubs progressing towards our stated strategy of building a 45-50 strong pub estate by 2013."

Trading Update The Capital Pub Company PLC is pleased to announce that trading has continued to be strong and in the first 44 weeks (ended 29 January 2011) of the current financial year, revenues were up 23% compared with the equivalent prior year period. The sales growth has been driven by organic growth in the existing estate, pubs that have benefited from refurbishments and the four new pub openings during the current financial year. Despite the adverse weather conditions during December, the bulk of the estate traded very well during this period and a number of outlets achieved record sales. The good trading pattern has continued throughout January and as a result of the Company's pubs being focused in London, the Directors remain confident about trading in the foreseeable future. The Company hopes to open its new site, The Goldsmiths Tavern in New Cross, London SE14 (the acquisition of which is due to complete on 7 February 2011) before Easter. This will bring the number of pubs being operated up to 32 and the Company has identified further sites for acquisition.

http://www.investegate.co.uk/Article.aspx?id=201102010700084190A

dp - Yes IAE could be good and the licences in the North Sea could be good plays too - Bought in at 9, 11 and 13.25 and waiting patiently - EO. at 15p isnt too shabby! Im in EO. too but only recently 112p - Another EO. would do nicely - it certainly has potential although the floods in Queensland will have a temporary impact I should imagine , as it did last time.

dp - have you read this ? http://grayshares.co.uk/graysinvestmentbloguk/2010/09/05/rheochem-swing-back-to-profit-thanks-debt-deal/

dp - do you use investegate for RNS ? http://www.investegate.co.uk/Index.aspx?searchtype=3&words=rhep

Some decent sized trades - buys and sells - creating SP movement - good to see

Nick Harding, CEO of Praesepe, said: "We are delighted to be acquiring a further fourteen sites from Noble. These additional sites provide us with an excellent platform for growth for Praesepe. The acquired sites complement our existing estate and provide the opportunity to deliver increased revenues and earnings without the cost and time delay of starting up entirely new Greenfield sites. This acquisition further consolidates our position as the fastest growing AGC operator in the UK and we are looking forward to integrating the new sites into our existing portfolio. We were pleased the Government announced the start of their consultation period on Category B3 Gaming Machines on 2 November 2010, and we are now awaiting further updates on the proposed deregulation. As previously announced, Category B3 machines are an important part of Praesepe's commercial offering and any increase in stakes would have a positive impact on our business and the potential for revenue growth. We look forward to the outcome of the consultation this year."

http://www.investegate.co.uk/Article.aspx?id=201101311540183937A

Geiger Counter (GCL)‘s subscription shares are finally converted.. They have hung over the market but are now cleared. Tomorrow starts the big push to get insto’s behind Geiger. Help yourselves at up to 120p if you reckon that uranium is the sector for 2011 – which I am told it most definitely is. TNAV is 125p.

Whatever your thoughts on BMD - he certainly has a following

MJW - Who knows - I thought it would bounce off 10 p but it only dropped to 6 and stayed there - thats when I bailed - I wouldnt want to rely on a bounce here

http://www.investegate.co.uk/Article.aspx?id=201101310700093144A

Highlights · US$ 15.8 million in sales for 2010 (US$ 12.5 million, 2009) · Total production of 2.2 million carats for 2010 (1.9 million carats, 2009) o Average grade of 59carats per tonne for 2010 (51 carats per tonne, 2009) · Commissioning of new cutting and polishing facility located at the TanzaniteOne mine · Q4 2010 : o Total production of 536,521 carats for Q4 2010 at 65 carat per tonne average grade o US$ 3.4 million in sales for Q4 2010

http://www.investegate.co.uk/Article.aspx?id=201101310700063062A

Not looking good unfortunately

Glyn Edwards, CEO of Antisoma, said: "We have not seen a benefit with AS1413. This is hugely disappointing for patients, investigators, investors and employees. We will now become smaller and focus on maximising the value of our other programmes."

Antisoma's pipeline of products comprises: * AS1411, a novel aptamer drug with potential in blood cancers and solid tumours; early data from the ongoing phase IIb trial in AML show this is likely to be inconclusive, so this trial will be terminated and development will be pursued through other approaches * DCAMs (dendritic cell autoimmune modulators), a programme of small-molecule kinase inhibitors in preclinical development with potential as oral therapeutics for autoimmune diseases, and * PPMID, a new and highly targeted approach to cancer treatment under preclinical development in a collaboration with The Institute of Cancer Research.